S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Join Morningstar today. It's Free.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.
|BioLineRx Announces Receipt of Notice of Allowance from USPTO for Patent Covering BL-5010, a Novel Treatment for Removal of Skin Lesions (2013/10/7)|
|BioLineRx Receives Approval to Commence Pivotal Trial for Novel Skin Lesion Treatment (2014/1/21)|
|BioLineRx Reports Third Quarter 2013 Financial Results ()|
|BioLineRx Reports Second Quarter 2013 Results (2013/8/6)|
|Edison grows its international biopharmaceutical presence with initiation of coverage of BioLineRx (2013/12/9)|
|BioLineRx to Present at the 2014 BIO CEO & Investor Conference in New York on February 10 (2014/2/3)|
|BioLineRx Announces Positive Preclinical Results for Novel Treatment for Chronic Myeloid Leukemia (2014/2/12)|
|BioLineRx Appoints Dr. Sandra Panem to Board of Directors (2014/2/24)|
|BioLineRx Prices $21.0 Million Underwritten Public Offering of its American Depositary Shares (2014/3/4)|
|BioLineRx Announces Underwritten Public Offering of its American Depositary Shares (2014/3/3)|
Click above to view more mutual fund data and stats for 5010 - Nippon Seiro Co Ltd.